Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Buzz on the Bullboards: The Summer of Uncertainty

Welcome back to Buzz on the Bullboards. After taking a short break to enjoy the sun, the bi-weekly review is back to keep you up-to-date on what the Stockhouse Community is discussing. It’s been a busy few weeks for markets and investors alike, with trade ...
Omri Wallach | June 27, 2019 |

Buzz on the Bullboards: Hot Sector Highlights

It has been a hot few weeks recently for most of North America, both for the weather and for investor discussion! The markets faced a rate cut in the US, ongoing trade disputes, a high for gold prices, and a potential bounce-back for the cannabis sector. Much of the d...
Omri Wallach | August 8, 2019 |

Buzz on the Bullboards: From innovating traffic enforcement to cancer breakthroughs

The past week on the TSX has been one for the books, with significant gains driven largely by advancements in the technology sector. The S&P 500 and NASDAQ have hit fresh highs, a clear sign of a hungry market bolstered by technology stocks. This momentum has put a spot...
Jonathon Brown | June 20, 2024 |

Deciphera's Shares Open 115% Higher on Phase 3 Ripretinib Results

Deciphera Pharmaceuticals announced positive top-line results from the INVICTUS pivotal phase 3 clinical study of ripretinib in patients with advanced gastrointestinal stromal tumors. Early this morning, clinical-stage biopharmaceutical company Deciphera Pharmaceutic...
Streetwise Reports | August 14, 2019 |

Aravive Shares Rise on Positive Patient Data from Phase 1b Ovarian Cancer Study

Shares of Aravive Inc. are trading higher after the firm posted positive data from the initial 12 patients enrolled in the Phase 1b portion of its study of AVB-500 used in the treatment of ovarian cancer. Today, in a late-breaking oral presentation at the European Soc...
Streetwise Reports | September 30, 2019 |

Exelixis Shares Climb 21% on Positive Phase 3 Advanced Kidney Cancer Study Results

Shares of Exelixis reached a new 52-week high price after the firm reported positive topline results from its Pivotal Phase 3 CheckMate -9ER trial evaluating Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) in previously untreated advanced ...
Streetwise Reports | April 21, 2020 |

Can Amazon stock retain its Magnificent Seven position?

Amazon.com Inc. (NDAQ:AMZN) is one of the S&P 500’s Magnificent Seven Amazon shares were up more than 85 per cent the past year and have doubled over the past five years Amazon’s target price is around US$200, implying an...
Coreena Robertson | April 17, 2024 |

Biotech's Topline Breast Cancer Data Impresses

Biotech's Topline Phase 3 HER2-Positive Breast Cancer Data 'Impresses' The results and commercial potential of the therapeutic are discussed in an H.C. Wainwright & Co. report. In an Oct. 22 research note, H.C. Wainwright & Co. analyst Andrew Fein reported that t...
Streetwise Reports | October 24, 2019 |

New Data Could Drive Use of Pancreatic Cancer Early Detection Test

The recent results and their implications are provided in an H.C. Wainwright & Co. report. In an Oct. 25 research note, H.C. Wainwright & Co. analyst Yi Chen reported that newly compiled data support the clinical utility of Interpace Diagnostics Group Inc.'s (IDXG:NA...
Streetwise Reports | October 30, 2019 |

Karyopharm Trades Up 60% on Positive Phase 3 Multiple Myeloma Results

Karyopharm Therapeutics shares set a new 52-week high price after the company reported that its Phase 3 BOSTON trial of XPOVIO® achieved significant increases in progression-free survival in patients suffering with multiple myeloma. Oncology-focused...
Streetwise Reports | March 3, 2020 |
1 2 3 4 5 6 7 8 9 10 ...